Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review
Lung cancer patients frequently develop brain metastases (BM). For example, approximately 30% of radically treated stage III non-small cell lung cancer (NSCLC) patients present with symptomatic BM in the course of their disease, despite being treated with radical chemoradiotherapy[1]. In metastatic NSCLC with an oncogenic driver, BM incidence is up to 60%[2]. BM incidence of small cell lung cancer (SCLC) patients is even higher (up to 80% at autopsy)[3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Haiyan Zeng, Lizza E.L. Hendriks, Wouter H. van Geffen, Willem J.A. Witlox, Danielle B.P. Eekers, Dirk De Ruysscher Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Small Cell Lung Cancer | Study